Five years ago, on March 11, 2020, the World Health Organization explained the outbreak of Covid-19 A global pandemic. The new Coronavirus, Suns-Dim-started as the “cluster of severe pneumonia cases with unknown causes”, which was reported in Wuhan, China, in December 2019. It had reported 118,000 cases in 114 countries by March 11.

Dr. Tedros Adhanom Ghebreyesus, who at the time was General Director in a media meeting that day said that “the WHO is deeply concerned with both the alarming spread and severe level levels as well as through the alarming inactivity”. He asked the leaders to move quickly Scale your emergency answersAnd say that “all countries can still change the course of this pandemic.”

Public health authorities such as the WHO and the US centers for the control and prevention of diseases played with critical roles during the entire pandemic during coordination Local health departments After recognizing, chasing and testing for the virus. The WHO and CDC websites Get unprecedented traffic Since they became invaluable sources for the latest resources for prevention, number of cases, hospital stays and deaths. The National health institutes was instrumental in the development of COVID-19 treatments and contributions to vaccine research.

Now, five years later The USA withdraw from the WHO.

At the same time, the United States with outbreaks of tuberculosis, a Resuscitation of measles Among non -vaccinated communities and the worst flu period in 15 years.

Much of the WHO work, the CDC and other public health authorities take place behind the scenes, which only occasionally attract the public attention. In order to put these roles in the right perspective, it can be helpful to examine public health before these uniform units existed.

https://www.youtube.com/watch?v=KZXEXCWYFGU

A spreading epidemic, slow communication

As the author of the book 2020 “”Construction of the outbreak: epidemics in the media and collective memory” And “Cover Covid: Media and Pandemic in the digital age“, Published in 2025, I examined in detail How the public health crises have developed. And through my research as a scientist for health communication, I analyzed the essential role of non -profit organizations and public authorities in protecting public health.

Both WHO and the CDC were set up in the 1940s. Before an international or even national network of public health authorities existed, there were no coordinated means of communication, external studies or formalized species to record data in geographical areas. Without a means of exchanging information, it was much more difficult for outbreaks and epidemics to be connected between the regions.

A remarkable example was the influenza pandemic from 1918, a fatal combination of influenza and pneumonia, which first appeared A basis of the Kansas Army in the spring of 1918. From there, the epidemic moved to overseas and spread until late summer throughout Asia and Europe. When it returned to the United States in August, the disease was displaced by the “Spanish flu”. The lack of media reporting on the outbreak of spring, coupled with the lack of illness tracking, meant that most people believed that the fatal tribes had started in Europe.

Nobody officially followed these outbursts until the disease returned with American troops in August 1918. In September, the US surgeon and the US public health service tried to do so Measure the size and gearbox from influenza by sending telegrams to state health officers.

At this point it was far too late for mass preparation. The few stories of the spring outbreaks had been buried in a flood of competing news about the World War. Therefore, people knew almost nothing about the angry illness until she infected her own city. Briefly to resources and caregivers, the municipalities had to create provisional hospitals and find healthy residents who care for the sick.

For example at the University of Kansas during influenza pandemic, professors of female professors Well -kept for sick students, faculties and employeesWashed bed linen and prepared food. Since agencies such as the WHO and CDC have not yet existed and the world war further hindered communication, only a few information in geographical regions was documented and shared, e.g.

The influenza pandemic quickly faded into the Collective memory of the publicPartly due to the lack of personal stories and follow-up stories, after cases were decreased-at least to Covid-19, a new public interest in the 100-year crisis aroused.

The polio epidemic saw a more coordinated reaction

From the 1930s, public health reactions to polio outbreaks showed the advantages of nationally coordinated efforts. The National Foundation for Infantile paralysis helped combat polio through fundraising, carried out campaigns to educate the public, to support scientific research and to help sacrifices from the acute hospital stage through rehabilitation. These efforts were particularly evident in the 1952 Polio epidemic.

In the summer of 1952 escalated US policy cases, Finally a total of 57,628 -More than a third of it included different levels of paralysis. The National Foundation for Infantile paralysis coordinated with local chapters of their organization throughout the epidemic. Together, the foundation held people over the growing epidemic, created polio -oriented hospital wings, recruited nurses and other members of the health professions and joint resources for the areas with outbreaks.

The widespread vaccination efforts led to a profound reduction in polio falls in the United States in the 1960s, which caused the National Foundation for Infantile paralysis Change his name and mission to the March of Dimes. The organization served as a model for non -profit organizations and public health authorities for communication and coordination between local and national companies.

The critical role of public health authorities

The CDC was opened in 1946 Representatives from 53 countries the constitution of the WHO. This global unit brought together countries through continents to combat monitoring, prevention, treatment and research by the disease.

When these agencies were extended into new areas of public health in the 1950s and 1960s, they reflected many of the approaches and strategies used by the National Foundation for Infantile paralysis: Persecution and recording of data publicly, to raise the public, to examine threats, to help in moments of crises and support scientific research. Together, the CDC and WHO have significantly improved public health from the Global extermination of smallpox and the decline of those in the vaccine dancing to the development and Implementation of HIV/AIDS treatments.

Before the Covid 19 pandemic, the roles of these agencies often did not attract much attention, since field agents traveled to examine something as routinely as Salmonella or as scary as hemorrhagic fever cases.

While Public opinions of the CDC and the Who were moving through the Covid 19 pandemicThe latest survey results show that the majority of Americans Trust of public health authorities At least to a certain extent. A survey of 2024 showed that almost 60% of American adults believe that the United States benefited from his WHO membership.

When infectious diseases come out of the spotlight and are considered less urgent, the critical roles of these public health authorities fade into the distant collective memory, similar to the pandemics of 1918 and Covid-19. People forget early enough the need for ongoing scientific research, educational programs and teams that can quickly react to local, national and international level.

The disease is still a threat because the outbreaks of measles, tuberculosis, influenza and other pathogens remind us. People are still sick or die of Covid-19: from March 1st, 6,725 people had died from Covid-19 in the USA especially in 2025 and almost 7.1 million died worldwide since January 2020.

Without strong, coordinated efforts between public health authorities, even small disasters can escalate in adult epidemics or even pandemics, for which the world will be far less prepared.

Selenium is a nutrient that plays a Crucial role in human healthIn the case of contribution to thyroid and immune function, the DNA repair in addition to cardiovascular and cognitive health.

It acts as An antioxidant – Substances that protect cells from unstable molecules that may damage DNA, proteins and cell membranes. It may even protect against cancer.

Selen is significant Trace element Found in living organisms, soil and plants, and your body only needs a small amount of it to work. The really useful dietary allowance for selenium is in adults 55 micrograms per dayWith an upper limit of 400 micrograms. In comparison, adults need between 900 and 10,000 micrograms on daily basis Copper, one other trace elementAnd in between 8,000 to 40,000 micrograms of the trace element zinc.

A surplus or an absence of selenium can have significant health consequences. In my work as Pharmaceutical science researcherMy colleagues and I examine the potential use of selenium to extend the effectiveness of chemotherapy in cancer treatment.

A dose of selenium

Selen first discovered in 1817 Chemist Jöns Jacob Berzelius analyzed an impurity in a number of sulfuric acid that was produced in a factory in Sweden. Berzelius initially believed the fabric the element, but he finally realized that it was actually an unknown substance at the moment. He called the mineral afterwards SeleneThe Greek goddess of the moon, due to its similarity Tellurwhich had been named after the Roman goddess of the earth.

Selenium exists in each organic and inorganic forms. Organic compounds Contain carbon atoms and are typically derived from living organisms Inorganic compounds Do not have carbon atoms and usually come from non -living sources. Your cells chemically Convert between these forms perform different physiological functions.

Selenium deficiency is a significant health problemEspecially in regions with selenium floors corresponding to parts of China, Africa and Europe. Low selenium mirrors are connected Keshan diseasea fatal heart disease, and Kashin Beck diseasewhich affects joints and bones. The defect also weakens immune function and increases susceptibility to infections.

Consuming an excessive amount of selenium can also be an issue. Extension or excess environmental pollution can result in this Selenosis, a disease In symptoms corresponding to brittle hair and nails, digestive problems, rashes and neurological symptoms corresponding to irritability and tiredness. In severe cases, selentoxicity can result in organ failure and death.

Selenium has a narrow one Therapeutic windowThis is the dosage area that gives secure and effective treatment with minimal harmful uncomfortable side effects. For example, selenium can either increase or reduce the body Immune functionDepending on the dose. Adequate selenium values Strengthen your immune cells' Ability to combat infections and tumors, while excessive selenium intake can Suppress immune responses by damage to immunogeways.

Selen and cancer prevention

Selenium can have the potential to treat and stop cancer.

Scientists have examined an extended selenium role in cancer prevention. Initially suspected that a carcinogen was, later studies were determined Protective effects against liver damage. In the Nineteen Sixties. Researchers proposed This selenium could possibly be Is used to stop cancerAn idea that received further traction within the nineties.

Mixed results were achieved in large -scale clinical studies. The Selen- and Vitamin E Cancer Prevention Prevention Study Was a study with over 35,500 men who were carried out from 2001 to 2004. They found that the each day intake of selenium didn’t reduce the chance of prostate cancer and may even Increase the chance of prostate cancer For men with already high selenium mirrors.

Results of a study from 1983 to 1996, the one Nutrition of cancer studiesproposed selenium may Protection against prostate and other sorts of cancer. But researchers also observed a Increased incidence of non -melanoma -skin cancer Among the participants.

These contradictory results could be attributed to the several types of the selens in every test tested and to differences within the selenium mirrors of the essential lines among the many participants. Other studies have shown that selenium-contaminated water was in a community of Italy associated with an increased risk of melanoma.

Selen and cancer treatment

Selenium may have the potential to stop cancer from spreading the spread of cancer.

My research focuses on the potential of using selenium to complement chemotherapy for cancer treatment. Selen compounds corresponding to methylselenic acid or MSA and Seleno-L-Methionine or SLM are promising in terms of aiming proteins that promote the progression and treatment resistance of the tumor. Studies from my team and I even have found that MSA can Modulate crucial biochemical ways in reference to kidney cancer by reducing proteins that influence tumor growth and immune instructions. We have also observed that SLM Mai May May Slow growth of the kidney tumor for mice without toxic uncomfortable side effects.

In a clinical phase -1 study we found that much more essential Combining SLM with the chemotherapy drug Axitinib Was effective within the treatment of metastatic kidney cancer in patients with minimal uncomfortable side effects. Of the 27 patients we treated, greater than half shrank their tumors with a median overall survival of just about 20 months. These results suggest that selenium can have a synergistic influence on chemotherapy by making it more practical.

Further studies on how selenium can overcome the treatment resistance and which doses are optimal will illustrate its potential as a practical addition to cancer treatment.

Meet the best balance

Whether as an immune amplifier or potential treatment for diseases, the importance of selenium for human health is undeniable.

Eat Selenium -rich foods – How Brazil nuts, seafood, whole grains and eggs can assist to keep up an optimal nutrient content. In regions with selenium deficiency floors, an addition to medical supervision could also be obligatory.

The fantastic line between advantages and damage underlines the importance of balanced intake and personalized approaches to selenium complement. In the course of research, I imagine that Selens becomes a various role in health.

Health employees from across the Bay Area gathered at Stanford University Monday morning as a part of a nationwide “pop-up clinic to treat genocide-related illnesses” and in protest of the continued war in Gaza.

About 40 people gathered on Stanford Medical School's Alumni Lawn around 10 a.m. Several doctors wore their white coats, wore keffiyehs around their necks and cloth shields on their backs. The signs read “No more bomb, no more hospital, no more child” and other statements in red ink.

RELATED: Israel arrests the director of one in all the last functioning hospitals within the northern Gaza Strip in a raid

“As a Muslim, Arab, American mother and doctor, she witnessed the targeted killing of health care providers, the killing of civilians, children and even young men and women, and the targeted destruction of hospitals and bombing of ambulances by the Israeli Defense Forces.” is absolute disgusting,” said Dr. Yusra Husain, assistant professor at Stanford Medical School. “We as healthcare providers refuse to normalize genocide. Every death and every child burned is a shock to our system.”

According to a press release, the gathering was a part of a nationwide Doctors Against Genocide movement, wherein doctors from across the country called in sick to demand an end to the war in Gaza and the discharge of 450 health care employees held captive by Israel. After just a few speeches, the gathering moved to White Plaza at Stanford, where doctors and community members once more arrange their table and signs.

The gatherings saw the inauguration of the Kamal Adwan Pop-up Clinic for Genocide-Related Illnesses, where health professionals distributed guidance on learn how to treat genocide-related illnesses: “the immense moral injury, emotional trauma and grief experienced by health workers, “when we witness genocide and other human rights violations against patients and colleagues, for example in Gaza,” says a printed guide distributed on the stand. The guide also advised doctors on learn how to provide medical certificates to employees searching for leave for “genocidal disease” and gave patients advice on learn how to request these certificates.

Dr. Rupa Marya, a professor of medication at UCSF, said she was suspended from her job for “speaking about the genocide in Gaza.” She added that her research examined how chronic inflammatory diseases similar to heart disease and dementia are brought on by damage from societal conflict.

“Racism creates structures in society that drive inflammation in marginalized people who bear the greatest burden of chronic inflammatory disease,” she said. “Genocide is the most egregious and blatant expression of racism and is literally making us sick.”

“Attacks on health infrastructure and health workers accelerate the destruction of the Palestinian people and are an act of genocide,” Marya added.

UCSF didn’t immediately reply to a request for comment on Marya's suspension Monday afternoon.

The pop-up clinic offered steps of a “treatment plan”: The plan calls for attacks on hospitals in Gaza to stop, for kidnapped medical examiners to be released, and for medical examiners in Gaza to be protected. It also calls for an arms embargo in addition to aid and reconstruction for the areas occupied by Israel.

“I am tired of genocide, tired of the silence of our government as it pushes the murderous attack while making grand promises of peace and humanity,” said Hilton Obenzinger, a retired professor and associate director emeritus of the Chinese Railroad Workers in North America Project Stanford . “I'm tired of how our government doesn't listen to its own people who want to end the war, how it doesn't listen to the United Nations, how it doesn't listen to human rights groups, and how it doesn't listen to American Jews who are crying out for real peace. “Ceasefire.”

Hussain also outlined protesters' specific demands for Stanford: that the university condemn “the genocide in Palestine” and the attacks on health care employees and facilities, condemn “ongoing medical apartheid in Palestine,” and adopt an ethical procurement policy that eliminates Includes purchases from corporations “involved in Israeli war crimes,” she said.

Stanford University officials didn’t immediately reply to a request for comment on the list of demands.

“There are absolutely no words that can adequately express the pain and depravity of this violence,” said Rochelle Mclaughlin, a former adjunct professor at San Jose State University’s College of Health and Human Sciences who recently resigned. “I implore my colleagues in academia and health to speak out against genocide.”

Mclaughlin added that she was “deeply horrified, heartbroken and angry” as she witnessed massacres and mutilations of youngsters within the Palestinian territories.

“We cannot and will not give up our care for each other, and as we care for each other, this violence makes us sick, and so we take up this cause to heal, to address our own inflammation, and to help each other,” Marya said. “This genocide is literally making us all sick.”

Originally published: January 6, 2025 at 3:33 pm PST

Diabetes occurs when the body fails to manage its blood sugar levels. One type of diabetes causes the body to not produce insulin in any respect. Called Type 1 diabetes or T1DThis autoimmune disease occurs when the body's immune system thinks its own insulin-producing cells are foreign and kills them. On average, T1D could cause this in patients lose a mean of 32 years of healthy life.

Current treatment for T1D includes lifelong insulin injections. Although it’s effective, patients taking insulin are prone to developing low blood sugar levels, which might result in symptoms akin to tremors, irritability, hunger, confusion, and dizziness. In severe cases, seizures or lack of consciousness may occur. Real-time blood glucose monitors and injection devices will help prevent low blood sugar levels by controlling insulin secretion, but they don’t work for some patients.

A treatment is given for these patients Islet transplantation will help higher control blood sugar levels by giving them each recent insulin-producing cells and cells that prevent glucose levels from falling too low. However, it is proscribed by the supply of donors and the necessity to use immunosuppressive drugs. Only about 10% of T1D patients are suitable for islet transplantation.

In my work as Diabetes researchermy colleagues and I even have discovered that producing islet cells from stem cells will help overcome transplant challenges.

History of islet transplantation

Islet transplantation for type 1 diabetes FDA approval in 2023 after greater than a century of research.

Insulin-producing cells, also called beta cells, are positioned within the so-called pancreatic regions Langerhans Islands. They are present in cell clusters that produce other hormones involved in metabolism, akin to: B. Glucagon, which increases blood sugar levels; somatostatin, which inhibits insulin and glucagon; and ghrelin, which signals hunger. anatomist Paul Langerhans discovered islets in 1869, while studying the microscopic anatomy of the pancreas, he found that these cell clusters were markedly different from other cells.

The path to islet transplantation has faced many hurdles since pathologist Gustave-Édouard Laguesse first speculated about it what role islands play in hormone production within the late nineteenth century. In 1893, researchers tried to treat a 13-year-old boy who was dying of diabetes with one Transplanting the pancreas in sheep. While they noted a slight improvement in blood sugar levels, the boy died three days after the procedure.

Interest in islet transplantation was renewed in 1972, when scientists Paul E. Lacy successfully transplanted islets in a diabetic rat. Thereafter, many research groups attempted islet transplantation in humans, with no or limited success.

In 1999, transplant surgeon James Shapiro and his team successfully transplanted islets in seven patients in Edmonton, Canada, by transplanting large numbers of islets from two to 3 donors directly and using immunosuppressive drugs. Through the Edmonton ProtocolThese patients were capable of manage their diabetes without insulin for a 12 months. Until 2012 Over 1,800 patients have undergone islet transplants based on this system, and roughly 90% survived the seven years of follow-up. The first FDA-approved islet transplant therapy based on the Edmonton Protocol.

Stem cells as a source for islets

Islet transplantation is now considered a minor surgical operation by which islets are injected right into a vein within the liver using a catheter. As easy because it could seem, it exists many challenges related to the procedure, including high cost and limited availability of donor islets. The transplant also requires lifelong use of immunosuppressants that allow the foreign islets to live and performance within the body. However, using immunosuppressants also increases the chance of other infections.

To overcome these challenges, researchers are considering using stem cells to create a limiteless source of islets.

There are two forms of stem cells For islet transplants, scientists use: embryonic stem cells, or ESCs, and induced pluripotent stem cells, or iPSCs. Both species can mature into islands within the laboratory.

Each has benefits and downsides.

There are ethical concerns about ES because they’re derived from dead human embryos. ESC transplantation would still require immunosuppressive drugs, limiting their use. Therefore, researchers are working on either encapsulating ESC islands or making mutations to guard them from the body's immune system.

Conversely, iPSCs are obtained from skin, blood or fat cells of the transplant patient. Since the transplant involves the patient's own cells, there isn’t a must take immunosuppressants. But the price of generating iPSC islands for every patient represents a significant obstacle.

Challenges with stem cell islands

While iPSCs could theoretically eliminate the necessity for immunosuppressive drugs, this method has yet to be tested within the clinic.

T1D patients with genetic mutations that cause the disease cannot currently use iPSC islets since the cells that will be used to create stem cells can also carry the identical disease-causing mutation of their islet cells. Many gene editing tools available could possibly remove these mutations and generate functional iPSC islands.

In addition to the challenge of genetic optimization, price is a significant problem in islet transplantation. The transplantation of islet cells from stem cells is dearer than insulin therapy on account of the upper costs Manufacturing costs. Efforts to scale the method and make it less expensive also include creation Biobanks for iPSC matching. This would allow iPSC islets for use for multiple patient, reducing costs by eliminating the necessity to generate freshly modified islets for every patient. Embryonic stem cell islands have the same advantage in that the identical batch of cells may be used for all patients.

There can also be a risk that tumors will form from these stem cell islands after the transplant. Until now, Laboratory studies on rodents And clinical trials on humans rarely suffer from cancer. This suggests that the likelihood of those cells forming a tumor is low.

However, many rounds of research and development are required before stem cell islands may be utilized in the clinic. It's a tricky road, but I consider just a few more tweaks will help researchers beat diabetes and save lives.

When Victor Ambrose And Gary Ruvkun When they found a brand new molecule within the Nineteen Eighties that they called microRNA, it was an intriguing change from what had been called “microRNA” for a long time central dogma of molecular biology.

Recognized with the 2024 Nobel Prize in Physiology or MedicineAmbros and Ruvkun had identified a brand new form of genetic material that modified researchers' understanding of gene regulation.

RNA, like DNA, is a type of genetic material that consists of individual nucleotides linked together into chains. According to the central dogma, genetic information flows in a single direction: DNA is transcribed into RNA, and RNA is translated into proteins. But in a significant departure from central dogma, some RNAs are never translated or encoded into proteins.

MicroRNA is a form of these so-called non-coding RNAs. These are short sections of genetic material that don’t themselves code for a particular protein, but fairly control the RNAs that code for proteins. In fact, microRNAs turn certain genes on and off.

I dedicated my scientific profession to know how RNA works, partly because research on RNA lags behind other macromolecules comparable to DNA and proteins. The Nobel Prize recognition for microRNA molecules highlights each their importance in biology and their promise as a possible treatment for various diseases, including cancer.

MicroRNAs and disease

Scientists consider microRNAs as Master regulators of the genome because of their ability to bind to and alter the expression of many protein-coding RNAs. In fact, a single microRNA can regulate between 10 and 100 protein-coding RNAs. Instead of translating DNA into proteins, they’ll as an alternative bind to protein-coding RNAs to silence genes.

The reason microRNAs can regulate such a various pool of RNA is because of their ability to bind to focus on RNAs with which they don’t perfectly match. This signifies that a single microRNA can often regulate a pool of targets, all involved in similar processes within the cell, leading to an enhanced response.

Because a single microRNA can regulate multiple genes, many microRNAs can contribute to disease after they stop functioning.

In 2002, researchers first identified the role of dysfunctional microRNAs within the disease of patients with a particular form of blood and bone marrow cancer chronic lymphocytic leukemia. This cancer results from the Loss of two microRNAs normally involved in blocking tumor cell growth. Since then, scientists have identified over 2,000 microRNAs in humansa lot of that are altered in various diseases.

The field has developed a reasonably solid understanding of how microRNA dysfunction contributes to disease. Changing one microRNA can alter several other genes, leading to a wide range of changes that may overall alter the cell's physiology. For example, greater than half of all cancers show significantly reduced activity microRNA called miR-34a. Because miR-34a regulates many genes involved in stopping cancer cell growth and migration, lack of miR-34a may increase the chance of cancer.

Researchers are considering using microRNAs as a therapeutic against cancer, heart disease, neurodegenerative diseases and others. While the ends in the laboratory were promising, the introduction of microRNA treatments within the clinic was promising overcome several challenges. Many of those are related to inefficient delivery to focus on cells and poor stability, which limits their effectiveness.

Delivery of microRNA to cells

One reason it’s difficult to deliver microRNA treatments into cells is that microRNA treatments should be targeted to diseased cells while avoiding healthy cells. Unlike mRNA COVID-19 vaccines, that are taken up by scavenging immune cells whose job is to acknowledge foreign materials, microRNA treatments must trick the body into considering they will not be foreign to avoid an immune attack and change into the intended ones cells to achieve.

Scientists are exploring alternative ways to deliver microRNA treatments to their specific goal cells. One method that’s attracting a whole lot of attention relies on direct use Linking the microRNA with a liganda form of small molecule that binds to certain proteins on the cell surface. Compared to healthy cells, diseased cells can have a disproportionate variety of surface proteins or receptors. Ligands can subsequently help microRNAs reach diseased cells in a targeted manner while avoiding healthy cells. The first ligand approved by the US Food and Drug Administration to deliver small RNAs comparable to microRNAs, N-Acetylgalactosamine or GalNAcdelivers RNAs preferentially to liver cells.

To discover ligands that may deliver small RNAs to other cells, receptors should be found which can be expressed at sufficiently high levels on the surface of the goal cells. Typically, over one million copies per cell are required to attain sufficient delivery of the drug.

One distinguished ligand is folic acid, also called vitamin B9, a small molecule that’s critical during times of rapid cell growth, comparable to fetal development. Because some tumor cells have one million folate receptors, this ligand provides ample opportunity to deliver enough therapeutic RNA to combat various sorts of cancer. For example, my lab developed a brand new molecule called FolamiR-34a – folate linked to miR-34a – which reduced the dimensions of breast and lung cancer tumors in mice.

Making microRNAs more stable

Another challenge with using small RNAs is their poor stabilitywhich ends up in their rapid degradation. Therefore, RNA-based treatments are generally short-lived within the body and require frequent doses to keep up a therapeutic effect.

To overcome this challenge, researchers must Modification of small RNAs in alternative ways. While each RNA requires a particular pattern of modification, successful modifications can significantly increase their stability. This reduces the necessity for frequent dosing, which in turn reduces treatment burden and costs.

For example, modified GalNAc siRNAsone other type of small RNAs, reduces the dosage in non-dividing cells from every few days to once every six months. My team has evolved Folate ligands related to modified microRNAs for cancer treatment, which reduced the dosage from once every other day to once per week. In diseases comparable to cancer, where cells divide rapidly and quickly dilute the delivered microRNA, this increase in activity is a major advance in the sphere. We anticipate that this success will facilitate further development of this folate-bound microRNA as a cancer treatment in the approaching years.

Many laboratories are working to develop treatments based on the discoveries a long time ago by recent Nobel laureates Ambros and Ruvkun. While there continues to be much work to be done to beat the hurdles related to microRNA treatments, it is obvious that RNA holds promise as a therapeutic agent for a lot of diseases.

This is an updated version of an article originally published on November 29, 2023.

parents with any type of disability They are far more prone to have some form of interaction with the Child welfare system than other parents. This means they’re reported more often than other parents Child abuse and neglect and more likely Have abuse or neglect by child welfare staff credibly demonstrated. They are also more prone to have theirs Children placed in foster families and more likely permanently lose their parental rights.

More than One-third of moms with mental and developmental disabilities have contact with the kid welfare system inside 4 years of the birth of their child and roughly One fifth of all children in foster care have a parent with a disability.

However, there may be one There is little evidence that oldsters with disabilities abuse or neglect their children at higher prices than everyone else. Instead, there may be evidence that many young adults are being raised by a parent with a disability I actually have very positive childhood experiences.

New rules that got here into force in July 2024 provide the primary federal protections specifically for folks with disabilities. These latest rules prohibit discrimination against parents and caregivers with disabilities throughout the kid welfare system.

The government is changing these rules

I’m a Social work policy researcher which has been coping with measures affecting parents with disabilities since 2007.

In 2010, I discovered that three-quarters of states had laws stating that a parent could have a disability be used as a reason for termination of parental rights. Most of those state laws focused on parents with mental and developmental or psychological disabilities, although some also listed physical disabilities and other types.

Many of those laws were vague and used outdated language corresponding to “mental disability.”

A parent's disability is the one ground for termination of parental rights that focuses on the parent's situation. The rest focuses on behaviors. For example, there may be parental poverty not listed as a reason for termination of parental rights in any condition, but neglect – a behavior – is.

State laws were just one in every of the issues parents with disabilities faced related to child protection. For years it was unclear how the Americans with Disabilities Actthe federal law prohibiting discrimination based on disability applies to folks within the child welfare system. Until 2015, Most state courts have rejected ADA claims from parents with disabilities who believed they were being discriminated against.

In addition, most child welfare staff work receive no formal training to work with parents with disabilities. They are not trained to evaluate parenting skills or adapt to the services they normally offer, corresponding to: B. Providing training for folks at home or communicating information in easy language. You is probably not aware of the overwhelming evidence for this Parents with mental disabilities can learn parenting skills.

This has historically been the case led to many child welfare staff making decisions based on stereotypes or speculation.

One of the fundamental prejudices that oldsters with disabilities face is the “Presumption of unsuitability bias.” This is a typical bias that states that oldsters are incapable of raising children just because of their disability.

This bias can lead to child welfare professionals not bearing in mind that oldsters with disabilities relate to “parental support“ to support them in parenting, from adaptive cribs and baby monitors to home helpers. It also can cause Parents with disabilities are held to the next standard than others.

State laws that specifically discover a parent's disability as grounds for termination of parental rights, the dearth of federal protections, and widespread prejudice leave parents with disabilities vulnerable in encounters with the kid welfare system.

Gain national attention

Two federal actions within the early 2010s brought national attention to folks with disabilities.

Firstly, the National Council on Disabilitythe independent federal agency that advises the federal government on disability issues published a report in 2012 titled Rock the cradle. This report focused on the widespread discrimination faced by parents with disabilities; emphasized and called for a change in state child protection laws; and called for the appliance of ADA protections in child welfare cases involving parents with disabilities.

This report received many media attention and led to greater awareness of the plight of those parents.

Then, in 2015, the Department of Justice and the Department of Health and Human Services published guide Directing child welfare agencies to guard parents with disabilities from discrimination. This was the primary federal motion to point that the ADA and Section 504 of the Rehabilitation Act applied to child protection services.

This guidance followed the departmental investigation Massachusetts Department of Children and Families' Removal of a newborn baby from Sara Gordon, a young mother with a developmental disability, in 2012. The Justice Department and the Department of Health and Human Services found that the state agency assumed Gordon was unfit to care to deal with her child and unable to learn parenting skills. The state agency also failed to contemplate that Gordon had support systems in place. She lived together with her parents and her mother had quit her job to assist raise her.

Making Progress for Parents with Disabilities

The momentum to guard parental rights has led to some positive changes.

A couple of states have modified their very own child protection laws to deal with a few of these issues before the federal government takes motion by providing latest protections for folks with disabilities. In addition, the Department of Justice and the Department of Health and Human Services have entered into agreements with state agencies Oregon, Georgia And Massachusetts related to discrimination against parents with disabilities.

Despite these advances, there are parents with disabilities are still discriminated against by the kid welfare system in lots of parts of the country.

At the identical time, I actually have little doubt that the Federal Government Revise the provisions of Section 504 of the Rehabilitation Act is a large step forward for folks with disabilities.

In particular, it’s promising Section 84.60 of the Rule clarifies that discrimination on the premise of disability is just not permitted in any a part of the kid welfare process. Child welfare agencies across the United States must now be sure that they don’t make decisions based on speculation, stereotypes or generalizations.

When a baby welfare agency assesses how a baby is being raised due to changes in federal rule, the tools it uses have to be supported by research. Assessments have to be conducted by a certified skilled and tailored to the needs of the person parent. Agencies must be sure that parents with disabilities can take part in all services they provide. These services include parent-child visits, parenting skills programs, family reunification services, and placement of youngsters in foster care or within the care of one other relative.

Disabled advocacy groups applauded this latest regulation when it got here into force in the summertime of 2024.

I consider these latest rules will protect parents with disabilities when coping with child protection authorities. They may even make it easier for child welfare agencies and state courts to discover disability discrimination when it appears of their records or files.

A “close relative” of the damaging E. coli strain could offer a brand new treatment for urinary tract infections, researchers say.

Researchers at Texas A&M are working on developing a tool that harmless strains of E. coliwhich was first discovered within the Nineteen Seventies, is claimed to inhibit the expansion of harmful bacteria that cause urinary tract infections, in accordance with a university press release dated September 17.

According to the researchers, the great E. coli strain is helpful since it consumes all of the nutrients that bad E. coli and other urinary tract infection-causing bacteria resembling Staphylococcus have to survive.

“The urinary tract becomes so heavily colonized with the good strain that the harmful bacteria cannot grow, preventing urinary tract infections,” the researchers said within the press release.

The goal is to make use of a hydrogel device much like a contact lens and loaded with live E. coli bacteria that may “float freely in the bladder and slowly release” helpful bacteria into the urinary tract, stopping bad bacteria from thriving, the researchers said.

Continuous use of antibiotics in people vulnerable to frequent urinary tract infections, including those with spinal cord injuries and menopausal women, can have long-term “negative effects on the gut microbiome and overall health,” the researchers said.

“Using 'good' bacteria to fight 'bad' bacteria opens up all sorts of new treatment and prevention options, and not just for urinary tract infections,” Associate Professor Dr. Sarguru Subash said within the press release.

The project is a collaboration between researchers from the College of Veterinary Medicine and Biomedical Sciences and the College of Engineering at Texas A&M University.

©2024 The Charlotte Observer. Visit charlotteobserver.com. Distributed by Tribune Content Agency, LLC.

PHILADELPHIA — Julia O'Reilly was 5-foot-2, 190 kilos, suffered from prediabetes and hypertension. Her only real exercise was chasing her little ones.

She met together with her doctors, who prescribed weekly Ozempic injections for O'Reilly. She lost 22 kilos.

But without the load, her face became saggy, her cheeks sunken and dark circles formed under her eyes, O'Reilly said.

“The goal was to lose weight,” O'Reilly said, “not to look gaunt and sickly.”

Those who take medications like Ozempic – whether for medical or aesthetic reasons – often find that weight reduction ends in what’s now called the “Ozempic face.” The result: Medical spas are seeing a rise in inquiries from clients who use medications like Ozempic, Wegovy, Mounjaro and Zepbound.

“I didn't want to radically change myself,” O'Reilly said. “But I wanted my face to match this better version of myself.”

After consultation with the medical and cosmetic team at Center City Med Spa Skin Care Clinic Body+Beauty Laboratoryshe decided that fillers were the perfect solution to restore the youthful fullness that she felt Ozempic had robbed her face of.

An old treatment for a brand new problem

According to a Gallup poll 6% of adults within the US, or 15.5 million peoplereport using drugs like Ozempic and Wegovy to drop a few pounds. When they work as hoped, doctors say they curb appetite and cravings. The downside: lack of muscle mass, which ends up in an aged face.

“It’s a protein problem,” explains Dr. Marc Neff, medical director at Jefferson Health New Jersey's Weight Loss Surgery Program. “Protein is important for skin elasticity, muscle tone and overall skin health. It's really important that people who start taking these medications work with a nutritionist to keep protein levels high.”

Aestheticians have been using synthetic hyaluronic acid fillers—Restylane, Juvéderm, Sculptra, Belotero—to plump and hydrate aging skin for greater than 20 years. When synthetic hyaluronic acid is injected into cheekbones, jawlines and under the eyes, it mimics the natural version—Mother Nature's secret to dewy, fresh-looking skin.

The regular injections have also helped cancer and HIV patients gain more self-confidence.

Over the years, nonetheless, fillers have come under the identical scrutiny as weight-loss drugs. Too much of them can result in a fake-looking face – see any reality TV star – not to say bruising, itching and swelling. And then there's the unfair pressure to all the time look young: the very proven fact that they exist sends the message to those that select to not have fillers that aging is just not an option, when in fact it's our only viable selection.

For patients who’ve lost weight with the brand new drugs, it will probably also seem to be they’re making an inconceivable pact with the evil beauty gods, or an unwinnable game. For many, it’s a game they’re comfortable to play.

“I deal with this topic every week,” said Sarah Sidiqian aesthetic nurse who sees about three “Ozempic Face” patients per week at Body+Beauty Laboratoryin comparison with once a month before weight-loss drugs became popular. “They all want to restore lost facial volume.”

A $4,000 solution

Before Linda Weller, 67, began using Mounjaro, her face looked pretty good for her age, she said. But after she lost 60 kilos in a 12 months, it began to “look like a landslide” — regardless that her A1C dropped and she or he was in a position to stop taking her blood pressure medication.

“I didn't want to spend money on a facelift,” Weller said. “So I got my cheeks done.”

“I look great and feel great,” Weller said.

Candice Reid, registered nurse and owner of a Mount Airy Med Spa Nurse Candiesaid she can be using more injectable hyaluronic acid, especially on clients over 40 who’ve lost weight.

In addition to the hyaluronic injections, Reid injects platelet-rich plasma or PRPinto clients' cheeks and jawline to stimulate collagen growth. Collagen is some of the necessary proteins our bodies produce to stop skin sagging. Production slows down as we enter our 30s and drops dramatically in our 40s.

“You can't see where you're going to lose weight,” Reid said. “But you can add volume to the areas of your face that have been affected by fat loss.”

On a recent Monday afternoon, O'Reilly was able to perk up. Five syringes of Restylane — greater than $4,000 in total — sat on the doctor's counter. After Sidiqi cleaned and numbed O'Reilly's face, he injected Restylane into each of O'Reilly's temples to provide her contour and under each of her cheekbones to lift her. Sidiqi injected Restylane into O'Reilly's chin to round it out, after which she had her lips plumped up, but not an excessive amount of, since the exaggerated pout is out.

The dark circles under her eyes were gone. The unwanted emaciation was gone. In lower than an hour, O'Reilly had her younger face back. The results should last a couple of 12 months.

“I like the way I look,” O'Reilly said. “I'm very happy.”

Will O'Reilly come back? She's undecided. Looking young isn't low-cost. Like weight-loss drugs, fillers may have to be an everyday a part of her beauty routine if she wants to maintain her looks. She's only 35.

©2024 The Philadelphia Inquirer, LLC. Visit www.inquirer.com. Distributed by Tribune Content Agency, LLC.

Drugmaker Lykos Therapeutics announced on August 9, 2024 that the Food and Drug Administration refused to grant the corporate’s request for using MDMA-assisted therapy within the treatment of Posttraumatic stress disorderThis is the primary decision of its kind on an application for marketing authorization for a psychedelic drug.

Many investors and researchers were Predicting a Psychedelic BoomMDMA is just the primary of a variety of psychedelics within the drug development pipeline.

The FDA’s decision has Disappointed supporters of psychedelic therapyand the share prices of Psychedelics Industry Leaders with the announcement. However, the FDA made recommendations on how the applying might be improved in order that MDMA could receive approval in the long run.

Another setback followed a couple of days later when the journal Psychopharmacology three papers on MDMA-assisted therapy withdrawnand referred to “protocol violations that amount to unethical behavior,” particularly in a clinical trial.

The Conversation asked drug researchers Benjamin Y. Fong from Arizona State University on the implications of the FDA decision and what it means for the long run of psychedelic medicines.

What is MDMA and what forms of illnesses can it treat?

MDMA or midomafetamineis colloquially referred to as “molly” or “ecstasy.” Technically it’s an amphetamine – just like the energetic ingredient in the eye deficit hyperactivity disorder drug Adderall – but MDMA is commonly classified as a psychedelic. It is taken into account to be more pleasurable than other amphetamines and is a preferred party drug because of this. Some researchers check with MDMA as an “empathogen” or “feeling enhancer.”

While MDMA is currently a List I medicinal products – meaning the Drug Enforcement Administration considers it highly dangerous and has no recognized medical use – a series of clinical studies indicate the advantages of using MDMA together with talk therapy for Patients affected by PTSDThe FDA received breakthrough therapy status for MDMA-assisted therapy in 2017, which accelerated its development and review.

PTSD affects between 9 to 13 million people annually within the USA and no novel treatments developed for this disease.

Lykos Therapeutics submitted an application for FDA approval its version of MDMA-assisted therapy for PTSD in February 2024. In it, the drug is paired with a form of psychotherapy that “inner healing intelligence“, which Lykos defined as “a person’s innate ability to heal the wounds of trauma.”

Why did the FDA reject approval of Lykos’ MDMA-assisted therapy?

In June 2024, a FDA advisory committee voted overwhelmingly against the concept that the relevant clinical trials have proven the effectiveness of MDMA in treating PTSD. Equally crucial is the The committee also voted against the thought It has been shown that the advantages outweigh the risks, comparable to increased blood pressure and potential for abuse.

At the time, the advisory committee found fault with several points of Lykos' application. First, it pointed to the issue of “functional unblinding,” the undeniable fact that most trial participants would know whether or not they were taking a robust psychoactive substance, which might skew the outcomes. This is an issue with any psychoactive drug, and Lykos critics imagine the corporate must have followed FDA policy to make use of an “active placebo” – a placebo that also has psychoactive effects – for comparison in its earlier clinical trials.

The panel also asked questions on the shape of psychotherapy used alongside MDMA, in addition to ethical concerns about various types of misconduct in Lykos' studies. In certainly one of the corporate's studies, a participant reported sexual misconduct by the therapists involved.

The FDA is just not sure by the votes of such advisory bodies, however it follows her leadTherefore, Friday’s decision was not an enormous surprise.

What does the FDA’s decision mean for the long run of MDMA?

The FDA requested a additional Phase 3 studythe phase of clinical trials wherein the security and effectiveness of a specific treatment is rigorously demonstrated as compared to straightforward treatment.

Lykos said the corporate will request a review of the choice and discuss the FDA's recommendations with the agency to make sure the corporate is on the proper track.

Lykos CEO Amy Emerson, who described the choice as “deeply disappointing,” believes that “several years” to perform the brand new process.

But with the journal Psychopharmacology Withdrawal of three articles related to this workLykos has a difficult road ahead of him.

What impact could this decision have on the approval of other psychedelic drugs?

A outstanding psychedelics company, Compass Pathways, is widely considered next in line for FDA approval of a psychedelic drug, with Phase 3 clinical trials for its synthetic psilocybin are well underway. Other corporations are preparing Phase 3 trials of their very own proprietary compounds.

Following the advisory panel’s ruling in June, Compass stated that it not mate his drug with a therapy just like the one Lykos carried out. Another company claimed that it has a “better study design that is more consistent with FDA guidelines.”

Other psychedelic corporations clearly imagine they’ll succeed where Lykos failed.

Are there any special challenges related to psychedelics?

The FDA’s decision was more about Lykos' specific approach than an entire rejection of psychedelics for therapeutic use.

Yet developing psychedelic drugs is inherently a fragile process. The drugs induce a profoundly altered state that puts people in a vulnerable position. Some people within the industry I've spoken to imagine that, given the character of the experience, it's almost inconceivable to avoid accusations of impropriety.

Most research also combines psychedelic drugs with some type of therapy or relief, and because the FDA has made clear, their role Evaluate medicinesnot the psychotherapies that may accompany it.

The interaction between the drugs and the human think about treatment is the topic of some debate. Lykos' missteps in its application make clear among the ways wherein corporations involved in developing psychedelic drugs face unique obstacles on the road to FDA approval.

BOSTON — Liam Hendriks had his pants down as he spoke. He was wearing his underpants, but his uniform was all the way down to his knees. He had just made his first bullpen appearance of the 12 months last Wednesday, a momentous step forward for any pitcher getting back from Tommy John surgery. Yet he stood within the Boston Red Sox locker room and refused to think about the occasion serious and even noteworthy.

How did his arm feel?

“Enclosed,” he said.

Was there an additional adrenaline rush when climbing a hill?

“Not really,” he replied.

What did you notice during rehab?

“How boring this is,” said Hendriks with a serious expression.

None of it got here across as dismissive. It was just laughable, a break from the monotony for Hendriks, his teammates and even the assembled reporters. He was chatting with a packed huddle of television cameras and microphones, all due to a 15-pitch bullpen three hours before game time. To Hendriks' credit, he didn't roll his eyes. He didn't travel from Australia, through years of baseball obscurity and rounds of cancer treatment, to have fun just a few pregame fastballs within the bullpen.

“I don't know if the coaches love me or want to kill me,” Hendriks said. “Every day I have to tell them to let me do more and they try to keep me at a normal level.

“That sucks.”

He longs for moments of greater significance and is confident that they will come.

Numbers help with any baseball story, and Hendriks' profession is told through his three All-Star appearances, two Reliever of the Year awards and 116 profession saves. His backstory is told through the 14 teams and 6 major league organizations that saw him come and go before anyone gave him credit for pitching the ninth inning. He is the one graduate of Australia's Sacred Heart College to ever play in the most important leagues, and he was drafted 4 times and traded three more times before most individuals had even heard of him. And yet here he’s, a survivor in additional ways than one.

For Hendriks, the last 20 months have revolved entirely around 4 rounds of chemotherapy, a six-game minor league rehab stint weeks later and his emotional return to the most important leagues last May. He made 4 good appearances in June before undergoing season-ending Tommy John surgery in August after which becoming a free agent.

“Theoretically, I have a new elbow,” Hendriks said within the spring. “So I still have 10 (years) ahead of me.”

Now 35, Hendriks is decided to prove himself again. He signed a two-year contract with the Red Sox because they promised him two things: They believed he could pitch this season, they usually wanted him to spend most of his rehab with the most important league team. And that's exactly what Hendriks did. On the road, at home, all through spring training. He didn't do his rehab at some fancy, far-flung facility; he threw in the sector, sat at his corner locker, and cracked jokes on the bullpen bench. Cancer treatment kept him away from other people for much too long last 12 months. But he doesn't wallow in self-pity. He doesn't ask questions.

“I've never been a big 'why me' person,” Hendriks said. “I think it was inevitable that I would have something to do with my elbow. Unfortunately, I also struggled with a lot of other issues that same year, but it is what it is. There's nothing I can do to change it. All I can do is go to the park every day with a positive attitude and hopefully rub off on some of the younger guys here.”

When Hendriks arrived at Red Sox training camp, he was given a goal of 64 mph, meaning a pitcher who normally throws a 95 mph fastball must be throwing about 64 mph when he's seven months post-Tommy John surgery. In his early days of spring training, nonetheless, he was throwing — “My surgeon probably won't be happy about this,” Hendriks said — within the mid-70s.

“Not consistent!” Hendriks clarified. “Consistently low 70s. But still, the jump from my previous time was a bit too high. … A few times I was a bit too strong in the paint. But I'd rather go too far than do too little.”

That's the experience of Liam Hendriks. Numbers don't do justice to what he does on the mound and off the sector. He's a savage with bulging veins who screams obscenities and trash talks, but he's also a teddy bear who builds Lego, is caring and cracks jokes.

Given these extremes, the December 2022 cancer diagnosis got here as a shock. Stage 4 non-Hodgkin lymphoma. Doctors told Hendriks he could expect six rounds of chemotherapy. He's proud that he only needed 4. He can't remember the precise date his last round began, only that it was the Chicago White Sox's first home game and he was purported to be of their bullpen, not in any hospital. He had a bone marrow biopsy in late April and started rehab the primary week of May.

His elbow lasted slightly over a month afterward.

In fact, Hendriks knew his elbow was causing problems long before it cracked. He first learned of a small tear in his UCL in 2008. He had pitched for greater than a decade without tearing it, but when he got back into the swing of things following cancer treatment – after a full six months off – he realized something was improper.

“He didn't care,” said Lucas Giolito, a former White Sox teammate and current Red Sox teammate. “A lot of guys would say in the training room or something, 'Oh, that hurts.' He said, 'I'm just going to keep going until it breaks.'”

Was there ever a thought to guard it after you've been through a lot to get back on the mound and the choice to a club looms?

“No. Hell no,” said Hendriks. “I'm not treating it like a baby.”

Hendriks said he has now turn into convinced that he’s most vulnerable to injury when he holds back.

“The elbow was definitely gone,” he said. “So I'm not going to sit there and try to rehab for another six weeks and then not come back. If it's gone, it's gone. If not, it's not gone. I was pretty sure it was already over, but I was hoping that maybe it was a little bit of scar tissue and if that breaks off at the right time, I'll be OK. It wasn't.”

This offseason, the White Sox declined a $15 million club option, making Hendriks a free agent. It's not unusual for pitchers recovering from Tommy John surgery to sign two-year deals so that they can really contribute within the second 12 months. When Hendriks spoke to interested teams this winter, nonetheless, he made it clear that these weren't negotiations for 2025.

“We made it very clear that we cannot approach the matter with this attitude,” said Hendriks. “Some teams got in touch and then simply disappeared.”

Hendriks expects to pitch for the Red Sox in August. He signed a two-year contract that guarantees him $10 million but in addition features a $12 million option for 2026. When he signed, Hendriks had already began playing catch along with his physical therapist. Hendriks said he was less anxious about his elbow than about throwing the ball to a non-baseball player. But Hendriks hit his partner within the chest, and the immediate feedback was that Hendriks was not “muscular,” meaning he stayed loose and didn’t tense up. The movement was as natural as ever.

When Hendriks talks about limits, he only talks about crossing them. From Australia to the All-Star Game. From being declared waivers to signing long-term contracts. From terminal cancer to a faster-than-expected recovery. From Tommy John surgery to a fastball that was too strong in spring training. Now a 15-pitch bullpen and a tongue-in-cheek mini-press conference.

Does the sunshine at the top of a Tommy John tunnel look different than the sunshine at the top of a cancer tunnel?

“Uh, in my eyes, it's the same thing,” Hendriks said in spring training. “There's still an end goal. There's still a goal that I have to come back from. It's just a little bit of a slower process.”

Hendriks shouldn’t be a man who sits back and waits, and that's exactly what he's needed to do for much of the last 12 months and a half. He's programmed to throw the ninth pitch. Talk to him again when the time finally comes.

“It's not that (rehab) takes a long time. I can handle a long time,” said Hendriks. “I can't handle slowness. And it's the slowness that really makes me angry.”